0001209191-14-059112.txt : 20140922 0001209191-14-059112.hdr.sgml : 20140922 20140922201343 ACCESSION NUMBER: 0001209191-14-059112 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20140919 FILED AS OF DATE: 20140922 DATE AS OF CHANGE: 20140922 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Horizon Pharma plc CENTRAL INDEX KEY: 0001492426 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 272179987 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: ADELAIDE CHAMBERS STREET 2: PETER STREET CITY: DUBLIN STATE: L2 ZIP: 8 BUSINESS PHONE: 011-353-1-649-8521 MAIL ADDRESS: STREET 1: ADELAIDE CHAMBERS STREET 2: PETER STREET CITY: DUBLIN STATE: L2 ZIP: 8 FORMER COMPANY: FORMER CONFORMED NAME: HORIZON PHARMA, INC. DATE OF NAME CHANGE: 20100520 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: GREY MICHAEL G CENTRAL INDEX KEY: 0001240122 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-35238 FILM NUMBER: 141114964 MAIL ADDRESS: STREET 1: C/O SGX PHARMACEUTICALS, INC. STREET 2: 10505 ROSELLE STREET CITY: SAN DIEGO STATE: CA ZIP: 92121 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2014-09-19 0 0001492426 Horizon Pharma plc HZNP 0001240122 GREY MICHAEL G C/O HORIZON PHARMA PLC ADELAIDE CHAMBERS, PETER STREET DUBLIN L2 8 IRELAND 1 0 0 0 Stock Option (Right to Buy) 3.95 2014-09-19 4 A 0 5265 A 2022-06-07 Ordinary Shares 5265 5265 D Stock Option (Right to Buy) 2.37 2014-09-19 4 A 0 20000 A 2023-05-30 Ordinary Shares 20000 20000 D Stock Option (Right to Buy) 15.96 2014-09-19 4 A 0 20000 A 2024-06-26 Ordinary Shares 20000 20000 D Stock Option (Right to Buy) 7.48 2014-09-19 4 A 0 10530 A 2014-09-28 Ordinary Shares 10530 10530 D Acquisition in connection with the merger (the "Merger") contemplated by the Transaction Agreement and Plan of Merger among Horizon Pharma, Inc., Vidara Therapeutics Holdings LLC, the Issuer (formerly known as Vidara Therapeutics International Ltd.), Hamilton Holdings (USA), Inc. and Hamilton Merger Sub, Inc. Pursuant to the Merger, the outstanding securities of Horizon Pharma, Inc. are being canceled and automatically converted into securities of the Issuer. The Reporting Person's disposition of securities of Horizon Pharma, Inc. in the Merger will be reported on a separate Form 4. The stock option vested in 12 equal monthly installments following the grant date, and is fully vested and exercisable. In connection with the Merger, the stock option originally granted by Horizon Pharma, Inc. has been converted into an option to purchase the same number of ordinary shares of the Issuer at the same exercise price and on substantially the same terms. The stock option vests in 12 equal monthly installments following the grant date of 6/27/2014. The stock option vests in 36 equal monthly installments following the grant date of 9/29/2011. /s/ Paul W. Hoelscher, Attorney-in-Fact 2014-09-22